{
    "2018-04-03": [
        [
            {
                "time": "2018-03-29",
                "original_text": "Why GlaxoSmithKline Stock Rose in the Week Ended March 29",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "Stock Rose"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Gilead",
                        "Novartis",
                        "Cancer Drugs"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "What Analysts Recommend for Novartis in March 2018",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Recommend",
                        "Novartis"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "The Swiss Stock Market Begins The Week With A Substantial Loss",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Substantial Loss"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Xgeva",
                        "EU Approval"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-20",
                "original_text": "Better Buy: Acadia Pharmaceuticals vs. Eli Lilly",
                "features": {
                    "keywords": [
                        "Acadia Pharmaceuticals",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-25",
                "original_text": "Will These Drugs Reach Blockbuster Status?",
                "features": {
                    "keywords": [
                        "Drugs",
                        "Blockbuster Status"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}